Format

Send to

Choose Destination
Clin Pharmacol Ther. 2012 Nov;92(5):613-21. doi: 10.1038/clpt.2012.102. Epub 2012 Sep 19.

The TGF-β pathway as an emerging target for Chagas disease therapy.

Author information

1
Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.

Abstract

Transforming growth factor-β (TGF-β) influences the development of myocardiopathy in Chagas disease through regulation of (i) parasite invasion of heart cells, (ii) an intracellular parasite cycle, (iii) inflammation and immune response, (iv) heart fibrosis and remodeling, and (v) gap junction modulation and heart conduction. In this review, we discuss the rationale for developing TGF-β signaling-interfering therapies as adjuvant approaches for the management of the cardiac alterations of Chagas disease-affected patients.

PMID:
22990752
DOI:
10.1038/clpt.2012.102
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center